Indian stocks: Visit www.stage2stocks.com →

Mustang Bio, Inc.

Stage 4 · Declining · week 55

As of Oct 22, 2026, Mustang Bio is in Stage 4, the downtrend phase, now in week 55 (since Sep 22, 2025). It closed at $0.37, 75.4% below its 52-week high and below its 200-day average, which is falling.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. More about the company

$0.37
-5.58% today
$2.8M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 47w
S4 43w
S4 57w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 47w → S1 9w → S4 43w → S1 11w → S4 57w current
Total tracked: 166 weeks across 5 stage runs.

MBIO among Biotechnology449th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…449MBIOStage 4 · wk 5513−27.8%
vs 52W High
-75.4%
$0.37 lo$1.50 hi
75.4% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 55
1w13w26w
Week 55, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-48.0%
200 DMA: $0.71 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.94x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-27.8%
3M
-34.3%
6M
-51.6%
YTD
-65.5%
1Y
-76.2%
Scan Membership
Breakout Watch
Latest: 2023-03-03
6 appearances in last 60 days. First seen: 2019-09-23.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 55 · Vol 0.94x
2026-10-21S4
Wk 55 · Vol 0.92x
2026-10-20S4
Wk 55 · Vol 0.33x
2026-10-19S4
Wk 55 · Vol 0.28x
2026-10-16S4
Wk 54 · Vol 0.93x
2026-10-15S4
Wk 54 · Vol 0.99x
2026-10-14S4
Wk 54 · Vol 5.49x
2026-10-13S4
Wk 54 · Vol 1.00x
2026-10-12S4
Wk 54 · Vol 1.87x
2026-10-09S4
Wk 53 · Vol 3.52x
2026-10-08S4
Wk 53 · Vol 3.74x
2026-10-07S4
Wk 53 · Vol 0.61x
Moving averages & range
50 DMA
$0.50
200 DMA
$0.71
52W High
$1.50
52W Low
$0.37
5D Low
$0.37
Resistance levels (recent highs)
20d High
$0.52
60d High
$0.61
120d High
$0.80
250d High
$1.50
Next resistance
+40.9%
to 20d High
ROE
-58.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.4

Mustang Bio: quick answers

What stage is Mustang Bio in?

As of Oct 22, 2026, Mustang Bio (MBIO) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 22, 2025 and is in week 55. What the four stages mean

Is Mustang Bio in an uptrend?

No. Mustang Bio is in a Stage 4 downtrend. It trades 48.0% below its 200-day average, which is falling.

How far is Mustang Bio from its 52-week high?

Mustang Bio closed at $0.37 on Oct 22, 2026, 75.4% below its 52-week high of $1.50. Its 52-week low is $0.37.

How has Mustang Bio performed over the past year?

As of Oct 22, 2026, Mustang Bio is down 76.2% over the past year and down 65.5% so far in 2026.

Which sector and industry is Mustang Bio in?

Mustang Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.